Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEG Characteristics of Chronic Pain in SCI
NCT06531837Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2024
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of esketamine, remifentanil and flurbiprofen in chronic pain (4 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: EEG Spectral Characteristics up to 3 hours. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
esketamineremifentanilflurbiprofen
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT06531837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531837.